<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104065</url>
  </required_header>
  <id_info>
    <org_study_id>C-421</org_study_id>
    <nct_id>NCT00104065</nct_id>
    <nct_alias>NCT00124592</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CuraGen Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <brief_summary>
    <textblock>
      CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under&#xD;
      investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring&#xD;
      side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem&#xD;
      cell transplant. The objective of this Phase II trial is to evaluate the safety and efficacy&#xD;
      of CG53135-05 when administered as a single dose to patients at risk for developing oral&#xD;
      mucositis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Stomatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG53135-05, velafermin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ages &gt; 18 yrs&#xD;
&#xD;
          -  Patients undergoing high dose chemotherapy with or without radiation therapy treatment&#xD;
             as conditioning for autologous hematopoietic stem cell transplantation. The&#xD;
             conditioning regimens include at least one of the following: high dose melphalan (Mel&#xD;
             200), busulfan, or etoposide, with or without total body irradiation.&#xD;
&#xD;
          -  Patients with Karnofsky performance scores &gt; or = 70%&#xD;
&#xD;
          -  Informed consent for participation in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who weigh &lt; 33 kg&#xD;
&#xD;
          -  Premenopausal female patients who are pregnant, lactating or are likely to become&#xD;
             pregnant&#xD;
&#xD;
          -  Patients with active medical conditions that preclude autologous hematopoietic stem&#xD;
             cell transplantation&#xD;
&#xD;
          -  Patients diagnosed with active acquired immunodeficiency syndrome (AIDS) or Hepatitis&#xD;
             B/C&#xD;
&#xD;
          -  Patients with known hypersensitivity to recombinant protein therapeutics&#xD;
&#xD;
          -  Patients who have taken CG53135-05, palifermin or other investigational drugs in the&#xD;
             past 30 days&#xD;
&#xD;
          -  Patients who have untreated symptomatic dental infection&#xD;
&#xD;
          -  Patients with a history of sensitivity or allergy to E. coli-derived products&#xD;
&#xD;
          -  Patients with WHO Grade 3 or 4 oral mucositis (OM)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 22, 2005</study_first_submitted>
  <study_first_submitted_qc>February 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2005</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral mucositis</keyword>
  <keyword>oncology - supportive care</keyword>
  <keyword>mouth diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

